Real-time monitoring of dynamic biological processes in the body is critical to understanding disease progression and treatment response. These data, for instance, can help address the lower than 50% response rates to cancer immunotherapy. However, current clinical imaging modalities lack the molecular contrast, resolution, and chronic usability for rapid and accurate response assessments. Here, we present a fully wireless image sensor featuring a $2.5{\times }5$ mm2 CMOS integrated circuit for multicolor fluorescence imaging deep in tissue. The sensor operates wirelessly via ultrasound (US) at 5-cm depth in oil, harvesting energy with 221-mW/cm2 incident US power density (31% of FDA limits) and backscattering data at 13 kb/s with a bit error rate $\lt 10{^{-6}}$ . In situ fluorescence excitation is provided by micro-laser diodes controlled with a programmable on-chip driver. An optical front-end combining a multi-bandpass interference filter and a fiber optic plate (FOP) provides >6 OD excitation blocking and enables three-color imaging for detecting multiple cell types. A $36{\times }40$ pixel array captures images with <125-$\mu $ m resolution. We demonstrate wireless, dual-color fluorescence imaging of both effector and suppressor immune cells in ex vivo mouse tumor samples with and without immunotherapy. These results show promise for providing rapid insight into therapeutic response and resistance, guiding personalized medicine.
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.
The glioblastoma tumor-immune microenvironment (TIME) is an immunosuppressive barrier to therapy that encumbers glioblastoma responses to immune checkpoint inhibition (ICI). Immunosuppressive cytokines, protumor macrophages and myeloid cells, and exhausted T cells are all hallmarks of the glioblastoma TIME. In this study, we integrated spatial and single-cell analyses of patient-matched human glioblastoma samples before and after ICI treatment with genetic, immunologic, single-cell, and pharmacologic studies in preclinical models to show that interleukin 6 (IL6) neutralization reprograms the glioblastoma TIME to sensitize mouse glioblastoma allografts to ICI and radiotherapy. Rare human glioblastomas that achieved clinical responses to ICI had lower pretreatment IL6 levels compared with glioblastomas that did not respond to ICI. Diverse immunostimulatory gene therapies suppressed local IL6 levels in mouse glioblastoma allografts, and IL6 from glioblastoma cells and the tumor microenvironment was associated with reduced survival in preclinical models and in patients. IL6 blockade with a neutralizing antibody transiently sensitized mouse glioblastoma allografts to ICI by decreasing immunosuppressive regulatory T cells and increasing MHCII+ monocytes, CD103+ migratory dendritic cells (DC), CD11b+ conventional DCs, and effector CD8+ T cells. IL6 blockade plus ICI sensitized mouse glioblastoma allografts to immunostimulatory ablative radiotherapy. Together, these data suggest that IL6 signaling contributes to ICI resistance in glioblastoma and provides a combination treatment strategy that could be used for patients. Significance: Integration of spatial and single-cell analyses of glioblastoma samples with immunologic, single-cell, and pharmacologic studies showed that IL6 neutralization reprograms the immune microenvironment to sensitize glioblastomas to ICI and radiotherapy.
Resistance to immune checkpoint inhibitors (ICIs) is common, even in tumors with T cell infiltration. We thus investigated consequences of ICI-induced T cell infiltration in the microenvironment of resistant tumors. T cells increased in ICI-resistant tumors following treatment as did neutrophils, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL-1 Receptor 1 (IL1R1), enabling a synergistic response to IL-1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting neutrophils. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo . Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a novel mechanism of ICI resistance, wherein treatment-induced T cell activity can drive resistance in tumors responsive to IL-1 and TNFα, with important therapeutic implications. Statement of Significance: Although T cell-infiltrated cancers are frequently resistant to immune checkpoint inhibitor therapies, mechanisms of resistance beyond T cell exhaustion remain unclear. Here, we reveal the functional significance of tumor- infiltrating T cells in resistant tumors, which surprisingly instruct immunosuppressive inflammation in mouse and human cancers responsive to IL-1 and TNFα.
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.